---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/43495895.md"
description: "No need to try and ride the mRNA concept wave right now unless you have incredible day-trading skills and a direct line to the exchange. With that effort, it's better to think about what corporate capabilities are needed for this path to succeed if mRNA truly has a future.$Tempus AI(TEM.US)? $XTALPI(02228.HK)?$10X Genomics(TXG.US)?"
datetime: "2026-08-19T16:15:25.000Z"
locales:
  - [en](https://longbridge.com/en/topics/43495895.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/43495895.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/43495895.md)
author: "[輸棟樓的韭菜](https://longbridge.com/en/profiles/10647684.md)"
generator: "portal-rs"
---

# No need to try and ride the mRNA concept wave righ…


### Related Stocks

- [TEM.US](https://longbridge.com/en/quote/TEM.US.md)
- [02228.HK](https://longbridge.com/en/quote/02228.HK.md)
- [TXG.US](https://longbridge.com/en/quote/TXG.US.md)

## Comments (18)

- **幻想日进斗金 · 2026-08-20T05:39:09.000Z**: Bro, why can't I trade?
  - **卖飞专业** (2026-08-20T05:39:23.000Z): 🪜Try turning on global, that's just how I am
- **程宫_658 · 2026-08-20T01:05:11.000Z**: I actually bought txg with the leek bro... I originally bought it for under $10... Missed out on a 10-bagger just like that.
  - **程宫_658** (2026-08-20T01:18:11.000Z): What does Bro Leek think of RXRX?
  - **輸棟樓的韭菜** (2026-08-20T01:26:36.000Z): I haven't done enough due diligence on RXRX. RXRX leans towards AI-driven drug discovery. In the short term, its stock price, like that of conventional innovative pharma, heavily depends on whether th
  - **程宫_658** (2026-08-20T01:30:02.000Z): Thanks for the serious reply from Leek Bro.
- **不奋东西 · 2026-08-19T23:23:00.000Z**: Thanks to @输栋楼的韭菜I completely agree, and the reminder is spot on!I simply don't have the ability for day trading.I haven't done any research on the pharmaceutical sector or these specific tickers.I wouldn't buy them!I'm writing this to exercise my thinking skills and for tracking and
- **PANSUYIN · 2026-08-19T16:44:25.000Z · 👍 3**: Took a look, it's hardly an mRNA milestone. Long-chain compounds are virtually useless in refractory cancers due to the lack of targets; essentially, it acts as an adjuvant, making it hard to claim technological validation, as there are currently no mRNA-targetable points in cancer-related gene regu
  - **輸棟樓的韭菜** (2026-08-19T16:48:42.000Z): But operationally it's manageable. Relying on COVID vaccines for survival, yet still suspected by the vaccine faction and facing regulatory chokeholds; life is too hard.
  - **輸棟樓的韭菜** (2026-08-19T16:53:54.000Z): Additionally, it's not that there are no targets available; there are just too many, making it hard to know which ones to target effectively and how to deliver them. 🫠 This is also why TEM surged toda
  - **TracyMai** (2026-08-19T17:54:34.000Z): Should I continue holding TEM, or is it time to take profits?
- **周树人的交易员 · 2026-08-19T16:27:47.000Z**: Quick question: Can Jitai's AiLNP platform serve as one of the breakthrough players in addressing screw-like bottlenecks?
  - **輸棟樓的韭菜** (2026-08-19T16:35:44.000Z): Will it solve the issue of endogenous escape? I think there's a chance. However, it remains one of the better domestic solutions. Domestic mRNA is still jogging along, so let's wait and see how the gl
  - **周树人的交易员** (2026-08-19T16:42:08.000Z): Alright, let's first look at the progress of global second-generation breakthrough paths.
  - **輸棟樓的韭菜** (2026-08-19T16:43:43.000Z): I want something more direct. Do you feel that mRNA applications are currently concentrated on vaccine development? This business logic is tied to US health insurance and gene sequencing, which is one


---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**